Medications for Melanoma
by Editorial Staff and Contributors
The primary treatment for melanoma is surgical removal of the tumor. Although requiring further clinical trials, in some cases, immunotherapy or targeted therapy may be used in the treatment of advanced stages of melanoma.
Many combination therapies are currently in trials. People with advanced melanoma should be considered for enrollment in a trial for their own benefit as well as for the advancement of melanoma treatment. Thus far, no single investigative approach stands out as highly effective however, they all hold promise with rare patients showing durable responses. Most treatment protocols are evaluating combinations of adjuvant therapies, hoping to achieve a synergistic effect. Ongoing research into the biology of melanoma continues to suggest new drug targets that will block tumor progression or enhance host response.
Immunotherapy involves using medications or substances made by the body to increase or restore the body's natural defenses against cancer. It is also called biological response modifier (BRM) therapy . Examples include interferon, interleukin-2, ipilimumab, and melanoma vaccines.
Side effects include chills, fever, aches, depression, and fatigue. At times, these can be a significant barrier to successful treatment.
About half of melanomas have a gene mutation known as BRAF. This gene causes the body to make proteins that accelerate the growth of cancer cells. Targeted therapy uses medications to seek out the cells with the BRAF mutation and destroy them. Targeted therapy medications include:
Although these medications are not a cure for advanced melanoma, it can increase survival rate. The most common side effects are joint pain, fatigue, hair loss, rash, itching, sensitivity to the sun, and nausea.
Promising Therapies TOP
Researchers are currently studying new drugs and therapies to treat melanoma. Therapies being studied include:
Bedikian AY, Johnson MM, Warneke CL, et al. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. J Immunotoxicol. 2008;5(2):201-207.
Eggermont AM, Robert C. New drugs in melanoma: It's a whole new world. Eur J Cancer. 2011;47(14):2150-2157.
Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22(1):53-61.
Lens M. The role of vaccine therapy in the treatment of melanoma. Expert Opin Biol Ther. 2008;8(3):315-323.
Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17(22):6958-6962.
Melanoma. EBSCO DynaMed Plus website. Available at: http://www.dynamed.com/topics/dmp~AN~T115302/Melanoma. Updated August 26, 2016. Accessed October 6, 2016.
Melanoma skin cancer. American Cancer Society website. Available at:
...(Click grey area to select URL)
Updated January 17, 2013. Accessed April 8, 2013.
Stein JA, Brownell I. Treatment approaches for advanced cutaneous melanoma. J Drugs Dermatol. 2008;7(2):175-179.
Treatment options by stage. National Cancer Institute website. Available at:
...(Click grey area to select URL)
Updated March 29, 2013. Accessed April 10, 2013.
Last reviewed March 2016 by Mohei Abouzied, MD
Last Updated: 3/15/2015
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
To send comments or feedback to our Editorial Team regarding the content please email us at firstname.lastname@example.org. Our Health Library Support team will respond to your email request within 2 business days.